The Vanguard Group Discloses Position in Avadel Pharmaceuticals

The Vanguard Group, Inc. recently filed its Form 8.3, complying with the Irish Takeover Panel Act, revealing its position in Avadel Pharmaceuticals plc. As of October 23, 2025, Vanguard holds a 5.67% stake in Avadel, translating to 5,525,048 ordinary shares. This move signifies Vanguard's noteworthy influence, considering ownership of over 1% in relevant securities mandates disclosure under the Act.

No short positions or engagements in cash or stock-settled derivatives were reported. Vanguard's transactions include the purchase of 1,119 shares at $18.56 each and the sale of 1,540 shares at the same price. No indemnity or option arrangements were disclosed, maintaining transparency in its dealings. The document highlights clear disclosure with no reported agreements connected to derivatives or voting rights.